Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine

Biomedicine and Pharmacotherapy

Volumn 58, Issue 5, 2004, Pages 325-337

  Kuroda, Yoshiki ^a   Nacionales, Dina C ^a   Akaogi, Jun ^a   Reeves, Westley H ^a   Satoh, Minoru ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Adjuvant; Autoimmunity; Pristane

Indexed keywords

ANTHRAX VACCINE; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CYTOKINE; CYTOMEGALOVIRUS VACCINE; FREUND ADJUVANT; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYDROCARBON; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 12; INTERLEUKIN 6; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; POLIOMYELITIS VACCINE; PRISTANE; SQUALENE; TUMOR NECROSIS FACTOR ALPHA;

ABSCESS; AUTOIMMUNITY; CYST; DERMATOMYOSITIS; ENVIRONMENTAL FACTOR; GRANULOMATOSIS; GUILLAIN BARRE SYNDROME; HEREDITY; HUMAN; HYPERGAMMAGLOBULINEMIA; IMMUNE RESPONSE; IMMUNOTOXICITY; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; NONHUMAN; POLYARTERITIS NODOSA; PRIORITY JOURNAL; REITER SYNDROME; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SIDE EFFECT; TISSUE INJURY; VACCINATION;

EID: 2942606120     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2004.04.009     Document Type: Article

References (106)

1. Audibert F.M., Lise L.D. Adjuvants: current status, clinical perspectives and future prospects. Immunol Today. 14:1993;281-284
2. Schwartz R.S. Autoimmunity and autoimmune diseases. Paul W.E. Fundamental immunology. 1993;1033-1097 Raven Press, New York
3. Edelman R. Vaccine adjuvants. Rev Infect Dis. 2:1980;370-383
4. Kenney R.T., Edelman R. Survey of human-use adjuvants. Expert Rev Vaccines. 2:2003;167-188
5. Singh M., O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol. 17:1999;1075-1081
6. Allison A.C. Squalene and squalane emulsions as adjuvants. Methods. 19:1999;87-93
7. Bennett B., Check I.J., Olsen M.R., Hunter R.L. A comparison of commercially available adjuvants for use in research. J Immunol Methods. 153:1992;31-40
8. Satoh M., Reeves W.H. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J Exp Med. 180:1994;2341-2346
9. Satoh M., Kumar A., Kanwar Y.S., Reeves W.H. Antinuclear antibody production and immune complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci USA. 92:1995;10934-10938
10. Satoh M., Richards H.B., Shaheen V.M., Yoshida H., Shaw M., Naim J.O., et al. Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane. Clin Exp Immunol. 121:2000;399-405
11. Anderson P.N., Potter M. Induction of plasma cell tumours in BALB/c mice with 2, 6, 10, 14-tetramethylpentadecane(pristane). Nature. 222:1969;994-995
12. Wooley P.H., Seibold J.R., Whalen J.D., Chapdelaine J.M. Pristane-induced arthritis. The immunologic and genetic features of an experimental murine model of autoimmune disease. Arthritis Rheum. 32:1989;1022-1030
13. Vingsbo C., Sahlstrand P., Brun J.G., Jonsson R., Saxne T., Holmdahl R. Pristane-induced arthritis in rats. A new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes. Am J Pathol. 149:1996;1675-1683
14. Whitehouse M.W., Orr K.J., Beck F.W.J., Pearson C.M. Freund's adjuvants: relationship of arthritogenicity and adjuvanticity in rats to vehicle composition. Immunology. 27:1974;311-330
15. Potter M., MacCardle R.C. Histology of developing plasma cell neoplasia induced by mineral oil in BALB/c mice. J Natl Cancer Inst. 33:1964;497-515
16. Cannon G.W., Woods M.L., Clayton F., Griffiths M.M. Induction of arthritis in DA rats by incomplete Freund's adjuvant. J Rheumatol. 20:1993;7-11
17. Satoh M., Kuroda Y., Yoshida H., Behney K.M., Mizutani A., Akaogi J., et al. Induction of lupus-related autoantibodies by adjuvants. J Autoimmun. 21:2003;1-9
18. Kuroda Y., Akaogi J., Nacionales D.C., Reeves W.H., Satoh M. Distinctive patterns of autoimmune response induced by different types of mineral oil. Toxicol Sci. 78:2004;222-228
19. Hamilton K.J., Satoh M., Swartz J., Richards H.B., Reeves W.H. Influence of microbial stimulation on hypergammaglobulinemia and autoantibody production in pristane-induced lupus. Clin Immunol Immunopathol. 86:1998;271-279
20. Satoh M., Hamilton K.J., Ajmani A.K., Dong X., Wang J., Kanwar Y., et al. Induction of anti-ribosomal P antibodies and immune complex glomerulonephritis in SJL mice by pristane. J Immunol. 157:1996;3200-3206
21. Richards H.B., Satoh M., Jennete J.C., Croker B.P., Yoshida H., Reeves W.H. Interferon γ is required for lupus nephritis in mice treated with the hydrocarbon oil pristane. Kidney Int. 60:2001;2173-2180
22. Calvani N., Satoh M., Croker B.P., Reeves W.H., Richards H.B. Nephritogenic autoantibodies but absence of nephritis in IL-12p35-deficient mice with pristane-induced lupus. Kidney Int. 64:2003;897-905
23. Richards H.B., Reap E.A., Shaw M., Satoh M., Yoshida H., Reeves W.H. B cell subsets in pristane-induced autoimmunity. Curr Top Microbiol Immunol. 252:2000;201-207
24. Satoh M., Shaheen V.M., Kao P.N., Okano T., Shaw M., Yoshida H., et al. Autoantibodies define a family of proteins with conserved double-stranded RNA-binding domains as well as DNA binding activity. J Biol Chem. 274:1999;34598-34604
25. Satoh M., Mizutani A., Behney K.M., Kuroda Y., Akaogi J., Yoshida H., et al. X-linked immunodeficient mice spontaneously produce lupus-related anti-RNA helicase A autoantibodies. but are resistant to pristane-induced lupus. Int Immunol. 15:2003;1117-1124
26. Richards H.B., Satoh M., Shaw M., Libert C., Poli V., Reeves W.H. Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J Exp Med. 188:1998;985-990
27. Satoh M., Shaheen V.M., Shaw M., Richards H.B., Reeves W.H. Role of bacterial lipopolysaccharide (LPS) in the induction of lupus autoantibodies by pristane. Arthritis Rheum. 41:1998;S178
28. Nakagawa K., Harrison L.C. The potential roles of endogenous retroviruses in autoimmunity. Immunol Rev. 152:1996;193-236
29. Armstrong M.Y.K., Ebenstein P., Konigsberg W.H., Richards F.F. Endogenous RNA tumor viruses are activated during chemical induction of murine plasmacytomas. Proc Natl Acad Sci USA. 75:1978;4549-4552
30. Akaogi J., Kuroda Y., Nacionales D.C., Reeves W.H., Satoh M. Ecotropic murine leukemia virus and exogenous mouse mammary tumor virus are not essential for pristane-induced lupus. Arthritis Rheum. 48:2003;2990-2992
31. Peng S.L., Moslehi J., Craft J. Roles of interferon-gamma and interleukin-4 in murine lupus. J Clin Invest. 99:1997;1936-1946
32. Haas C., Ryffel B., Hir M.L. IFN-γ is essential for the development of autoimmune glomerulonephritis in MRL/lpr mice. J Immunol. 158:1997;5484-5491
33. Satoh M., Weintraub J.P., Yoshida H., Shaheen V.M., Richards H.B., Shaw M., et al. Fas and Fas ligand mutations inhibit autoantibody production in pristane-induced lupus. J Immunol. 165:2000;1036-1043
34. Yoshida H., Satoh M., Behney K.M., Lee C.-G., Richards H.B., Shaheen V.M., et al. Effect of an exogenous trigger on the pathogenesis of lupus in NZB × NZW (F1) mice. Arthritis Rheum. 46:2002;2335-2344
35. Hultman P., Enestrom S., Pollard K.M., Tan E.M. Anti-fibrillarin autoantibodies in mercury-treated mice. Clin Exp Immunol. 78:1989;470-477
36. Michel M., Johanet C., Meyer O., Frances C., Wittke F., Michel C., et al. Familial lupus erythematosus. Clinical and immunologic features of 125 multiplex families. Medicine (Baltimore). 80:2001;153-158
37. Satoh M., Richards H.B., Reeves W.H. Pathogenesis of autoantibody production and glomerulonephritis in pristane-treated mice: an inducible model of SLE. Tsokos G.C., Kammer G. Lupus: Molecular and cellular pathogenesis. 1999;399-416 Humana Press
38. Naim J.O., Satoh M., Buehner N.A., Ippolito K.M., Yoshida H., Nusz D., et al. Induction of hypergammaglobulinemia and macrophage activation by silicone gels and oils in female A.SW mice. Clin Diagn Lab Immunol. 7:2000;366-370
39. Thompson S.J., Rook G.A.W., Brealey R.J., van der Zee R., Elson C.J. Autoimmune reactions to heat-shock proteins in pristane-induced arthritis. Eur J Immunol. 20:1990;2479-2484
40. Satoh M., Langdon J.J., Hamilton K.J., Richards H.B., Panka D., Eisenberg R.A., et al. Distinctive immune response patterns of human and murine autoimmune sera to U1 small nuclear ribonucleoprotein C protein. J Clin Invest. 97:1996;2619-2626
41. Satoh M., Treadwell E.L., Reeves W.H. Pristane induces high levels of anti-Su and anti-nRNP/Sm autoantibodies in BALB/c mice. Quantitation by antigen capture ELISAs based on monospecific human autoimmune sera. J Immunol Methods. 182:1995;51-62
42. Dighiero G., Lymberi P., Holmberg D., Ludquist I., Coutinho A., Avrameas S. High frequency of natural autoantibodies in normal newborn mice. J Immunol. 134:1985;765-771
43. Richards H.B., Satoh M., Knawar Y.S., Okano T., Jennette J.C., Reeves W.H. Disparate T cell requirements of two subsets of lupus-specific autoantibodies in pristane-treated mice. Clin Exp Immunol. 115:1999;547-553
44. Cox J.C., Coulter A.R. Adjuvants - a classification and review of their modes of action. Vaccine. 15:1997;248-256
45. Janeway C.A. Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol. 54:1989;1-13
46. Schijns V.E. Induction and direction of immune responses by vaccine adjuvants. Crit Rev Immunol. 21:2001;75-85
47. Singh M., O'Hagan D.T. Recent advances in vaccine adjuvants. Pharm Res. 19:2002;715-728
48. Degen W.G., Jansen T., Schijns V.E. Vaccine adjuvant technology: from mechanistic concepts to practical applications. Expert Rev Vaccines. 2:2003;327-335
49. Heeger P.S., Forsthuber T., Shive C., Biekert E., Genain C., Hofstetter H.H., et al. Revisiting tolerance induced by autoantigen in incomplete Freund's adjuvant. J Immunol. 164:2000;5771-5781
50. Kohashi O., Tanaka S., Kotani S., Shiba T., Kusumoto S., Yokogawa K., et al. Arthritis-inducing ability of a synthetic adjuvant, N-acetylmuramyl peptides, and bacterial disaccharide peptides related to different oil vehicles and their composition. Infect Immun. 29:1980;70-75
51. Zhang L., Mia M.Y., Zheng C.L., Hossain M.A., Yamasaki F., Tokunaga O., et al. The preventive effects of incomplete Freund's adjuvant and other vehicles on the development of adjuvant-induced arthritis in Lewis rats. Immunology. 98:1999;267-272
52. Schijns V.E. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol. 12:2000;456-463
53. Dupuis M., Denis-Mize K., LaBarbara A., Peters W., Charo I.F., McDonald D.M., et al. Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur J Immunol. 31:2001;2910-2918
54. Hamilton J.A., Byrne R., Whitty G. Particulate adjuvants can induce macrophage survival, DNA synthesis, and a synergistic proliferative response to GM-CSF and CSF-1. J Leukoc Biol. 67:2000;226-232
55. Takeda K., Kaisho T., Akira S. Toll-like receptors. Annu Rev Immunol. 21:2003;335-376
56. Beebe G.W., Simon A.H., Vivona S. Long-term mortality follow-up of Army recruits who received adjuvant influenza virus vaccine in 1951-1953. Am J Epidemiol. 95:1972;337-346
57. Robbins G.K., Addo M.M., Troung H., Rathod A., Habeeb K., Davis B., et al. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. Aids. 17:2003;1121-1126
58. Verdier F. Non-clinical vaccine safety assessment. Toxicology. 174:2002;37-43
59. Dodds W.J. More bumps on the vaccine road. Adv Vet Med. 41:1999;715-732
60. Hogenesch H., Azcona-Olivera J., Scott-Moncrieff C., Snyder P.W., Glickman L.T. Vaccine-induced autoimmunity in the dog. Adv Vet Med. 41:1999;733-747
61. Shoenfeld Y., Aron-Maor A. Vaccination and autoimmunity-'vaccinosis': a dangerous liaison? J Autoimmun. 14:2000;1-10
62. Descotes J., Ravel G., Ruat C. Vaccines: predicting the risk of allergy and autoimmunity. Toxicology. 174:2002;45-51
63. Offit P.A., Hackett C.J. Addressing parents' concerns: do vaccines cause allergic or autoimmune diseases? Pediatrics. 111:2003;653-659
64. Older S.A., Battafarano D.F., Enzenauer R.J., Krieg A.M. Can immunization precipitate connective tissue disease? Report of five cases of systemic lupus erythematosus and review of the literature. Semin Arthritis Rheum. 29:1999;131-139
65. Maillefert J.F., Sibilia J., Toussirot E., Vignon E., Eschard J.P., Lorcerie B., et al. Rheumatic disorders developed after hepatitis B vaccination. Rheumatology (Oxford). 38:1999;978-983
66. Ioannou Y., Isenberg D.A. Immunisation of patients with systemic lupus erythematosus: the current state of play. Lupus. 8:1999;497-501
67. Cooper G.S., Dooley M.A., Treadwell E.L., St Clair E.W., Gilkeson G.S. Risk factors for development of systemic lupus erythematosus: allergies, infections, and family history. J Clin Epidemiol. 55:2002;982-989
68. Cavallo T., Granholm N.A. Lipopolysaccharide from gram-negative bacteria enhances polyclonal B cell activation and exacerbates nephritis in MRL/lpr mice. Clin Exp Immunol. 82:1990;515-521
69. Battafarano D.F., Battafarano N.J., Larsen L., Dyer P.D., Older S.A., Muehlbauer S., et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum. 41:1998;1828-1834
70. Klippel J.H., Karsh J., Stahl N.I., Decker J.L., Steinberg A.D., Schiffman G. A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. Arthritis Rheum. 22:1979;1321-1325
71. Abu-Shakra M., Zalmanson S., Neumann L., Flusser D., Sukenik S., Buskila D. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. J Rheumatol. 27:2000;1681-1685
72. Schattner A., Ben-Chetrit E., Schmilovitz H. Poliovaccines and the course of systemic lupus erythematosus - a retrospective study of 73 patients. Vaccine. 10:1992;98-100
73. Ristow S.C., Douglas R.G. Jr, Condemi J.J. Influenza vaccination of patients with systemic lupus erythematosus. Ann Intern Med. 88:1978;786-789
74. Tarjan P., Sipka S., Marodi L., Nemes E., Lakos G., Gyimesi E., et al. No short-term immunological effects of Pneumococcus vaccination in patients with systemic lupus erythematosus. Scand J Rheumatol. 31:2002;211-215
75. Aron-Maor A., Shoenfeld Y. Vaccination and systemic lupus erythematosus: the bidirectional dilemmas. Lupus. 10:2001;237-240
76. Froehlich H., Verma R. Arthus reaction to recombinant hepatitis B virus vaccine. Clin Infect Dis. 33:2001;906-908
77. Rose N.R. Immunologic hazards associated with vaccination of humans. J Autoimmun. 14:2000;11-13
78. Howell C.D., Yoder T.D. Murine experimental autoimmune hepatitis: nonspecific inflammation due to adjuvant oil. Clin Immunol Immunopathol. 72:1994;76-82
79. Hotopf M., David A., Hull L., Ismail K., Unwin C., Wessely S. Role of vaccinations as risk factors for ill health in veterans of the Gulf war: cross sectional study. BMJ. 320:2000;1363-1367
80. Asa P.B., Wilson R.B., Garry R.F. Antibodies to squalene in recipients of anthrax vaccine. Exp Mol Pathol. 73:2002;19-27
81. Nash J.F., Gettings S.D., Diembeck W., Chudowski M., Kraus A.L. A toxicological review of topical exposure to white mineral oils. Food Chem Toxicol. 34:1996;213-225
82. Seery J.P., Carroll J.M., Cattell V., Watt F.M. Antinuclear autoantibodies and lupus nephritis in transgenic mice expressing interferon gamma in the epidermis. J Exp Med. 186:1997;1451-1459
83. Ioannou Y., Isenberg D.A. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 43:2000;1431-1442
84. Scheinecker C., Zwolfer B., Koller M., Manner G., Smolen J.S. Alterations of dendritic cells in systemic lupus erythematosus: phenotypic and functional deficiencies. Arthritis Rheum. 44:2001;856-865
85. Scott R.S., McMahon E.J., Pop S.M., Reap E.A., Caricchio R., Cohen P.L., et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature. 411:2001;207-211
86. Moser M., Murphy K.M. Dendritic cell regulation of TH1-TH2 development. Nat Immunol. 1:2000;199-205
87. Gensler T.J., Hottelet M., Zhang C., Schlossman S., Anderson P., Utz P.J. Monoclonal antibodies derived from BALB/c mice immunized with apoptotic Jurkat T cells recognize known autoantigens. J Autoimmun. 16:2001;59-69
88. Utz P.J., Gensler T.J., Anderson P. Death, autoantigen modifications, and tolerance. Arthritis Res. 2:2000;101-114
89. Ravnskov U. Hydrocarbon exposure may cause glomerulonephritis and worsen renal function: evidence based on Hill's criteria for causality. QJM. 93:2000;551-556
90. Harris D.T., Sakiestewa D., Titone D., Young R.S., Witten M. JP-8 jet fuel exposure results in immediate immunotoxicity, which is cumulative over time. Toxicol Ind Health. 18:2002;77-83
91. Hard G.C. Short-term adverse effects in humans of ingested mineral oils, their additives and possible contaminants - a review. Hum Exp Toxicol. 19:2000;158-172
92. Heimbach J.T., Bodor A.R., Douglass J.S., Barraj L.M., Cohen S.C., Biles R.W., et al. Dietary exposures to mineral hydrocarbons from food-use applications in the United States. Food Chem Toxicol. 40:2002;555-571
93. Spickard A. III, Hirschmann J.V. Exogenous lipoid pneumonia. Arch Intern Med. 154:1994;686-692
94. Cruickshank B. Follicular (mineral oil) lipidosis: I. Epidemiologic studies of involvement of the spleen. Hum Pathol. 15:1984;724-730
95. Rollins C.E., Reiber G., Guinee D.G.J., Lie J.T. Disseminated lipogranulomas and sudden death from self-administered mineral oil injection. Am J Forensic Med Pathol. 18:1997;100-103
96. Kumagai Y., Shiokawa Y., Medsger T.A. Jr, Rodnan G.P. Clinical spectrum of connective tissue disease after cosmetic surgery. Observations on eighteen patients and a review of the Japanese literature. Arthritis Rheum. 27:1984;1-12
97. Cabral A.R., Alcocer-Varela J., Orozco-Topete R., Reyes E., Fernandez-Dominguez L., Alarcon-Segovia D. Clinical, histopathological, immunological and fibroblast studies in 30 patients with subcutaneous injections of modelants including silicone and mineral oils. Rev Invest Clin. 46:1994;257-266
98. Lee J.Y., Lee K.S., Kim T.S., Yoon H.K., Han B.K., Han J., et al. Squalene-induced extrinsic lipoid pneumonia: serial radiologic findings in nine patients. J Comput Assisted Tomogr. 23:1999;730-735
99. Kohashi O., Aihara K., Ozawa A., Kotani S., Azuma I. New model of a synthetic adjuvant, N-acetylmuramyl-L-alanyl-D-isoglutamine-induced arthritis. Lab Invest. 47:1982;27-36
100. James J.A., Gross T., Scofield R.H., Harley J.B. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP induce spliceosomme autoimmunity. J Exp Med. 181:1995;453-461
101. Mozes E., Kohn L.D., Hakim F., Singer D.S. Resistance of MHC class I-deficient mice to experimental systemic lupus erythematosus. Science. 261:1993;91-93
102. Descotes J. Autoimmunity and toxicity testing. Toxicol Lett. 112-113:2000;461-465
103. Verdier F., Patriarca C., Descotes J. Autoantibodies in conventional toxicity testing. Toxicology. 119:1997;51-58
104. Hultman P., Enestrom S. Dose-response studies in murine mercury-induced autoimmunity and immune-complex disease. Toxicol Appl Pharmacol. 113:1992;199-208
105. Jacobson R.M., Adegbenro A., Pankratz V.S., Poland G.A. Adverse events and vaccination - the lack of power and predictability of infrequent events in pre-licensure study. Vaccine. 19:2001;2428-2433
106. Miller F.W., Hess E.V., Clauw D.J., Hertzman P.A., Pincus T., Silver R.M., et al. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum. 43:2000;243-249